Denosumab for tumor-induced hypercalcemia complicated by renal failure

Annals of Internal Medicine

Volumn 156, Issue 12, 2012, Pages 906-907

  Bech, Anneke ^a   de Boer, Hans ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CREATININE; DENOSUMAB; IMMUNOGLOBULIN G; SODIUM CHLORIDE;

ADULT; BONE MARROW BIOPSY; BONE PAIN; CALCIUM BLOOD LEVEL; CASE REPORT; CREATININE CLEARANCE; FATIGUE; FEMALE; HUMAN; HYDRATION; HYPERCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MULTIPLE MYELOMA; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 84862742019     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-12-201206190-00026     Document Type: Letter

References (5)

1. Lumachi F, Brunello A, Roma A, Basso U. Cancer-induced hypercalcemia. Anticancer Res. 2009;29:1551-5. [PMID: 19443365]
2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-9. [PMID: 21060033]
3. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010;25:440-6. [PMID: 19653815]
4. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32. [PMID: 21343556]
5. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813-22. [PMID:21353695]